Tags:
February 26, 2016 at 08:20PM
Open in Evernote
Friday, February 26, 2016
Thursday, February 11, 2016
Wednesday, February 3, 2016
Mobile Games Monetization: What successful game developers do differently | Insight | VentureBeat
Mobile Games Monetization: What successful game developers do differently | Insight | VentureBeat
Tags:
February 04, 2016 at 12:44AM
Open in Evernote
Mobile Games Monetization: What successful game developers do differently
Published December 16, 2015
Updated December 16, 2015
Updated December 16, 2015
Report Statistics
- Charts and Graphs: 31
Executive Summary
Mobile game monetization is perhaps the hardest task in business and technology today. The lucky few, it seems, rake in millions of downloads and – without exaggeration – billions of dollars. The masses struggle by with a trickle of downloads and a few pennies here and there.
But it doesn’t have to be that way.
We asked 176 game developers who have collectively published almost 1,100 games with more than 300 million downloads and $600 million in annual revenue to tell us what works best in mobile game monetization.
The results made two things very clear.
- Winning in mobile isn't about luck. The winners consistently win.
- There is a real pattern and formula the succesful developers are using to monetize apps.
Learn how to drastically increase your mobile revenue.
In this report we analyze the winners, and losers, in mobile monetization to uncover this winning formula.
The result is the exact information that will help you join the group of developers who are pulling in significant revenues … or at minimum, increase whatever revenues you are already generating.
With 39 pages, 31 graphs and over 5,000 words this report teaches you everything you need to know to monetize your app like the very best. Click Buy Now to pick up your copy today.
Tags:
February 04, 2016 at 12:44AM
Open in Evernote
Galera Ups Series B Financing to 42 Million
Galera Ups Series B Financing to 42 Million
2/3/2016 6:34:13 AM Galera Therapeutics Increases Series B Financing to $42 Million
Tags:
February 04, 2016 at 12:40AM
Open in Evernote
Galera Ups Series B Financing to $42 Million
- Funding to Support Development of Clinical Stage Dismutase Mimetics in the Treatment of Cancer Patients -
MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has received an additional $5 million in funding from Enso Ventures to bring its Series B financing total to $42 million. Enso Ventures joins existing investors New Enterprise Associates, Novartis Venture Fund, Novo Ventures, Correlation Ventures and Galera Angels.
“As we recently announced, our product lead GC4419, which is in randomized Phase 2b clinical development, was granted Fast Track designation for the prevention of radiation-related oral mucositis in patients with head and neck cancer. With Enso’s support, we will further expand the development of our dismutase mimetic portfolio.”
The investment capital will be used to advance the Company’s lead candidate GC4419 in a Phase 2b double-blind, randomized clinical trial that is currently enrolling head and neck cancer patients receiving chemoradiation therapy to prevent against oral mucositis (OM). The proceeds will also support continued development of Galera’s pipeline of selective dismutase mimetics to modulate oxygen metabolic pathways.
“We are delighted to have Enso Ventures join us,” said J. Mel Sorensen, MD, President and CEO of Galera. “As we recently announced, our product lead GC4419, which is in randomized Phase 2b clinical development, was granted Fast Track designation for the prevention of radiation-related oral mucositis in patients with head and neck cancer. With Enso’s support, we will further expand the development of our dismutase mimetic portfolio.”
“Galera’s clinical data with GC4419 in OM and the unmet need for these patients, combined with the strong management and investors really drove our interest,” said Sergei Petukhov, PhD, Partner at Enso Ventures. “We are excited to join our fellow investors in advancing this important product, and Galera’s broader efforts.”
About Oral Mucositis (OM)
OM is a common debilitating side effect of radiation treatment in head and neck cancer (HNC) patients. Severe OM, defined by the World Health Organization as Grade 3 or 4 OM, occurs in 60 to 80 percent of HNC patients who receive radiation therapy. Importantly, severe OM may result in interruptions in radiation treatment, which can compromise the otherwise good prognosis for tumor control in many of these patients. In addition, patients suffer significant pain, may develop serious infections, and may be unable to eat solid food or even drink liquids. Further, the costs of managing these side effects are substantial, particularly when hospitalization and/or surgical placement of PEG tubes to maintain nutrition and hydration is required. There is currently no drug approved to prevent or treat severe OM in head and neck cancer patients.
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc. is a clinical-stage biotechnology company, headquartered in Malvern, PA, focused on the development of breakthrough drugs targeting oxygen metabolic pathways. The Company's lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is initially focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer. For more information, visit www.galeratx.com.
Tags:
February 04, 2016 at 12:40AM
Open in Evernote
Takeda Wagers 1 Billion More on Mersana Therapeuticss Antibody Program
Takeda Wagers 1 Billion More on Mersana Therapeuticss Antibody Program
2/3/2016 7:50:49 AM Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer® Antibody-Drug Conjugates and XMT-1522
Tags:
February 04, 2016 at 12:40AM
Open in Evernote
Takeda (TKPYY) Wagers $1 Billion+ More on Mersana Therapeutics's Antibody Program
– Takeda obtains rights to Mersana’s XMT-1522 outside U.S. and Canada –
– Takeda to create additional Fleximer ADCs; Mersana to have a co-development option –
– Mersana to receive $40 million upfront, $20 million upon IND clearance and up to $20 million in equity investment –
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Mersana Therapeutics and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer® antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs.
“Takeda’s knowledge of oncology and commitment to ADCs as a key therapeutic approach make the company the best partner for us to progress our transformative platform and advance XMT-1522 into the clinic.”
XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Preclinical data suggest that XMT-1522 may have anti-tumor activity in patients with HER2 low-expressing cancers as well as in patients with HER2 high-expressing cancers that do not respond to currently available HER2-targeting therapies. Mersana anticipates filing an Investigational New Drug application (IND) for XMT-1522 with the U.S. Food and Drug Administration (FDA) in mid-2016.
“We believe XMT-1522 has the potential to make a dramatic difference for HER2 low-expressing patients who currently have limited treatment options, and are confident that our Fleximer-based technology can address significant patient needs not currently met by other ADC platform technologies,” said Anna Protopapas, President and Chief Executive Officer, Mersana. “Takeda’s knowledge of oncology and commitment to ADCs as a key therapeutic approach make the company the best partner for us to progress our transformative platform and advance XMT-1522 into the clinic.”
Takeda and Mersana will co-develop XMT-1522, and Mersana will lead execution of the Phase 1 trial. Mersana will retain full commercial rights in the United States and Canada while Takeda will have rights in rest of world. Beyond development and commercialization of XMT-1522, the expanded partnership also grants Takeda access to additional targets within Mersana’s Fleximer-based ADC platform, with Mersana retaining the right to select one program at the end of Phase 1 for co-development and co-commercialization in the United States. Takeda and Mersana will also work together, leveraging Takeda’s proprietary small molecule libraries, to identify and develop novel payloads that both parties will be able to use in new ADC therapies.
“This is our third collaboration with Mersana in less than two years. We see great potential for Mersana’s Fleximer technology, combined with our oncology expertise and resources, to extend the benefits of targeted therapy with ADCs to underserved cancer patient populations,” said Andrew Plump M.D., Ph.D., Chief Medical and Scientific Officer, Takeda. “We, along with the global oncology community, have made great strides in our fight against cancer, and we know that achieving our aspiration to cure cancer relies on great partnerships and innovation. We look forward to progressing these collaborations and, together, advancing the science of cancer care.”
Takeda signed agreements with Mersana through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc., under which, Mersana will receive an upfront payment of $40 million and an additional payment of $20 million upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20 million in equity in future rounds of Mersana financing.
About XMT-1522
XMT-1522 is an investigational, novel HER2-targeting therapy based on Mersana Therapeutics’ Fleximer® immunoconjugate technology, and carries approximately 15 proprietary auristatin payload molecules. Preclinical data have demonstrated significant anti-cancer activity in breast, gastric and non-small cell lung cancers, including in HER2 low-expressing tumor models refractory to currently available therapies. Mersana and Takeda are co-developing XMT-1522. Mersana will be responsible for commercialization in the United States and Canada; Takeda will be responsible in rest of world.
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana’s first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
About Takeda
Located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Tags:
February 04, 2016 at 12:40AM
Open in Evernote
Subscribe to:
Comments (Atom)